Cerebrolysin

What is Cerebrolysin?

Cerebrolysin is not a single peptide. It is a standardized mixture of low-molecular-weight peptides and free amino acids purified from pig brain tissue, made by the Austrian company Ever Pharma. It has been used for decades in Russia, parts of Europe, Asia, and Latin America for stroke recovery and dementia, given by injection under medical supervision. It is not approved by the FDA, so in the US it is not a standard therapy.

How Cerebrolysin works

The idea is neurotrophic mimicry. The peptide fraction is proposed to act like the body's own growth factors, engaging TrkB and TrkA receptors and downstream survival pathways (PI3K/Akt and MAPK/ERK) that keep neurons alive and support synaptic reorganization. Preclinical work also points to a shift toward anti-apoptotic signaling, meaning fewer neurons dying after injury. Because it is a mixture rather than one defined molecule, the exact active components are harder to pin down than with a single peptide.

What the research shows

Cerebrolysin has an unusually large clinical literature for a compound in this category, with dozens of trials and thousands of patients across stroke, dementia, and traumatic brain injury. The results are genuinely mixed. The most recent Cochrane review of acute ischemic stroke concluded it probably has little or no effect on death or serious disability, and criticized the risk of bias in many included studies. The more favorable signal is in vascular dementia and post-stroke cognition, where some reviews report modest stabilization. So this is not thin evidence, it is a lot of evidence pointing in different directions, with quality concerns.

Dosage and how it is used

There is no self-use protocol. In the countries where it is used, Cerebrolysin is given intravenously or intramuscularly in supervised courses over several weeks. This is a clinician-administered drug in its approved markets, not a compound with a standardized at-home dose.

→ How to reconstitute Cerebrolysin: calculator, units to draw & storage

Side effects and safety

Across the trials Cerebrolysin has generally looked well tolerated, and safety-focused meta-analyses have not found a clear increase in serious adverse events versus placebo. Because it is derived from animal brain tissue and given by injection, the usual injection-site and hypersensitivity considerations apply, and it is meant to be administered in a clinical setting. It is not FDA-approved.

• Large clinical literature, but results are mixed and many studies have quality concerns.
• A biological mixture from pig brain, not a single defined peptide, given by injection under supervision.
• Not FDA-approved. Legal and regulatory status varies by country. Verify independently.

Frequently asked questions

References

• Ziganshina LE et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews, 2020.
• Rejdak K et al. Modulation of neurotrophic factors in dementia, stroke and TBI: effects of Cerebrolysin. Medicinal Research Reviews, 2023.